[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620214":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":25,"locations":31,"responsibleParty":49,"collaborators":24,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":24,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":24,"enrollmentInfo":60,"targetDuration":24,"studyType":63,"phases":64,"briefSummary":67,"conditions":68,"keywords":24,"overallStatus":34,"whyStopped":24,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"3H Pharmaceuticals Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Stage I - dose escalation","EXPERIMENTAL","Dose escalation of 3H-10000 in patients with advanced solid tumors.",[13],"Drug: 3H-10000",{"label":15,"type":10,"description":16,"interventionNames":17},"stage II - expansion","Expansion evaluating the recommended dose and schedule of 3H-10000 identified from Stage I.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","3H-10000","3H-10000 will be administered by infusion Q2W in 28-day cycles.",[9,15],null,[26],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},"Shuchao Wu","CONTACT","0086-21-50895559","shuchao.wu@3hpharma.com",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Beijing Cancer Hospital","RECRUITING","Beijing","Beijing Municipality","100142","China","CN",{"type":41,"coordinates":42},"Point",[43,44],116.39723,39.9075,{"lat":44,"lon":43},[47],{"name":48,"role":28,"phone":24,"phoneExt":24,"email":24},"Lin Shen, MD",{"type":50,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100620214","phase-1-a-first-in-human-study-of-3h-10000-in-patients-with-unresectable-or-metastatic-solid-tumors-100620214",false,"NCT07354711","A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors","A Phase I\u002FII Study of 3H-10000 (an Anti-FGFR2b Antibody-Drug Conjugate) in Subjects With Unresectable or Metastatic Advanced Solid Tumors","Inclusion Criteria:\n\n* Subjects must be willing and able to sign the ICF and to adhere to the study visit schedule and other protocol requirements.\n* Male or female subjects aged ≥18 years at the time of signing the ICF.\n* According to RECIST v1.1, there is at least one measurable lesion.\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1 point.\n* Life expectancy of ≥3 months.\n\nExclusion Criteria:\n\n* Meningeal diseases or carcinomatous meningitis.\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage every two weeks or more frequently.\n* Having received treatment with other investigational drugs within 4 weeks prior to the first dose of the study drug.\n* Any AEs induced by prior anti-tumor therapy having not resolved to Grade 1 or lower (except for alopecia or any other Grade 2 AEs assessed by the investigator as not being associated with any safety risk).\n* Any corneal or retinal disease\u002Fkeratopathy assessed by the investigator as of clinical significance, including but not limited to bullous\u002Fband keratopathy, corneal abrasion, inflammation\u002Fulceration, and keratoconjunctivitis.","ALL","18 Years",{"count":61,"type":62},170,"ESTIMATED","INTERVENTIONAL",[65,66],"PHASE1","PHASE2","The study is being conducted to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 3H-10000 in the treatment of unresectable or metastatic solid tumors .",[69,70],"Lung Cancer","Stomach Cancer","2026-01-18",{"date":73,"type":74},"2026-01-21","ACTUAL",{"date":76,"type":74},"2026-01-04",{"date":78,"type":62},"2029-01",{"name":5,"class":6},1]